Nitamoon M60
Nitamoon M60 - Image 2
Nitamoon M60 - Image 3
,

Nitamoon M60

Contains:

  • Nateglinide BP 60 mg

  • Metformin Hydrochloride IP 500 mg
    Therapeutic Class: Meglitinide Class + Biguanide
    Schedule: Schedule H (Prescription Drug)

Nitamoon M60 combines two complementary antidiabetic agents to provide comprehensive glycemic control:

  • Nateglinide: A rapid-acting insulin secretagogue that reduces postprandial glucose spikes by mimicking early-phase insulin secretion.

  • Metformin: A first-line insulin sensitizer that primarily lowers fasting plasma glucose (FPG) by inhibiting hepatic gluconeogenesis and improving peripheral glucose uptake.

This dual mechanism targets both fasting and post-meal hyperglycemia, making Nitamoon M60 ideal for patients with Type 2 Diabetes Mellitus (T2DM) requiring flexible, physiologic glycemic management.

Usage of Nitamoon M60

  • Type 2 Diabetes Mellitus, especially in:

    • Early-stage T2DM uncontrolled on monotherapy

    • Patients with high postprandial glucose (PPG) and elevated fasting sugar

    • Individuals requiring a low hypoglycemia risk profile

    • Patients with irregular meal schedules

    • As a step-up from metformin monotherapy

Mechanism of Action

  • Nateglinide: Enhances glucose-dependent insulin secretion from β-cells, rapidly controlling mealtime glucose surges.

  • Metformin: Suppresses hepatic glucose output and enhances insulin sensitivity without causing weight gain or hypoglycemia.

Together, they offer dual-phase glycemic coverage:
➡ Metformin handles basal (fasting) glucose
➡ Nateglinide controls meal-induced (postprandial) excursions

Common Side Effects

  • Nateglinide-related: Mild hypoglycemia (less common than sulfonylureas), headache, upper respiratory symptoms

  • Metformin-related: Gastrointestinal upset, bloating, diarrhea, metallic taste

  • Rare: Lactic acidosis (extremely rare, but serious – caution in renal/hepatic dysfunction)

Precautions

  • Renal impairment: Assess renal function before initiation; avoid if eGFR <30 mL/min/1.73m²

  • Hepatic dysfunction: Use with caution due to lactic acidosis risk

  • Avoid in Type 1 diabetes or diabetic ketoacidosis

  • Caution in elderly or malnourished patients—monitor for hypoglycemia

  • Monitor vitamin B12 levels with long-term metformin use

Drug Interactions

  • Alcohol: Increases risk of lactic acidosis

  • Beta-blockers: May mask symptoms of hypoglycemia

  • Corticosteroids, diuretics: May increase blood glucose

  • CYP2C9 inhibitors/inducers: May affect Nateglinide metabolism

  • Contrast agents: Temporarily discontinue metformin before and after iodinated contrast procedures

Dosage and Administration

  • One tablet before each major meal, typically 2–3 times daily

  • Take 15–30 minutes before food

  • If a meal is skipped, skip the dose to prevent hypoglycemia

  • Dose titration based on glycemic response

Storage

  • Store below 25°C, in a cool, dry place

  • Protect from light and moisture

Patient Counselling Tips

  • Always take before meals—helps prevent post-meal sugar spikes

  • Do not skip meals after taking the medicine

  • Inform your doctor of any gastrointestinal symptoms, especially persistent nausea or fatigue

  • Monitor blood sugar levels regularly

  • Encourage lifestyle interventions (diet, exercise) alongside therapy

Positioning Benefits

  • Combines the fast-acting mealtime control of Nateglinide with the baseline glucose-lowering of Metformin

  • Low risk of sustained hypoglycemia

  • Suitable for young-onset diabetics and patients needing flexible meal-time management

  • May delay insulin initiation in early diabetics

Related products

Review My Order

0

Subtotal

Taxes & shipping calculated at checkout

Checkout